Discover top-quality products tailored for scientific and medical research. Request a personalized quote today
to enhance your projects.
| Product Code | Nalm-6; NALM 6; Nalm 6; NALM6; Nalm6; NALM-6-M1 |
| Species | Human |
| Cat.No | ABC-TC252S |
| Product Category | Tumor Cell Lines |
| Size/Quantity | 1 vial |
| Cell Type | Lymphocyte-like |
| Shipping Info | Dry Ice |
| Growth Conditions | 37 ℃, 5% CO2 |
| Source Organ | Peripheral Blood |
| Disease | Acute Lymphoblastic Leukemia |
| Storage | Liquid Nitrogen |
| Product Type | Human Leukemia Cell Lines |
NALM-6 is a human B-cell precursor acute lymphoblastic leukemia (B-ALL) cell line established in 1976 from the peripheral blood of a 19-year-old male patient during relapse. This cell line exhibits lymphoblastic morphology with small, round cells growing in suspension. It maintains a doubling time of 25–40 hours under standard culture conditions. NALM-6 displays a near-diploid genome (43–47 chromosomes) with a characteristic t(5;12)(q33.2;p13.2) translocation. NALM-6 expresses typical B-lineage markers including CD10, CD19, cytoplasmic CD79a (cyCD79a), and HLA-DR, while lacking T-cell antigens such as CD3. NALM-6 is tumorigenic in immunocompromised mice, forming systemic metastases in bone marrow, liver, and spleen.
When you publish your research, please cite our product as “AcceGen Biotech Cat.# XXX-0000”. In return, we’ll give you a $100 coupon. Simply click here and submit your paper’s PubMed ID (PMID).
NALM-6 cell line is widely used as a model for studying the biology and treatment of acute lymphoblastic leukemia. It offers an excellent platform for investigating B-cell development, oncogenic signaling, and therapeutic resistance. NALM-6 is particularly useful in examining the potential accumulation of oxidative clustered DNA lesions in leukemia cells following radiation exposure, simulating conditions seen in radiotherapy. These studies help elucidate damage responses in leukemia and aid to design novel therapeutic approaches, advancing both basic research and translational applications in hematologic malignancies.
NALM-6 cell line were originally isolated from peripheral blood of a patient with acute lymphoblastic leukemia (ALL) in relapse.
The seeding density is 2 × 10^5 cells/mL, it is recommended to keep the cell concentration within the range of 1 × 10^5 to 1 × 10^6 cells/mL for optimal growth.
The utility of Nalm-6 cells extends to studying the efficacy of therapeutic targets and existing drug resistance mechanisms, provides a unique way for researching the genomic landscape of the disease, including genomic instability and DNA repair mechanisms. It can also be helpful for studying the complex nature of acute leukemia.
The doubling time of NALM-6 cell line is around 35 to 40 hours. It could be different due to the batches.
